

**Supplemental Table S1: Global characteristics of patients with and without surgery in women (n=211)**

	No surgery (n=179)	Surgery (n=32)	Unadjusted <i>p</i> -value
<b>Baseline characteristics</b>			
Age, years ± SD	80.6 ± 7.0	77.2 ± 8.7	<b>0.015</b>
Body mass index (kg/m <sup>2</sup> )	27.7 ± 6.1	29.2 ± 6.2	0.198
Diabetes mellitus, n (%)	61 (34.1)	7 (21.9)	0.174
COPD, n (%)	36 (20.1)	9 (28.1)	0.308
Atrial fibrillation, n (%)	83 (46.4)	13 (40.6)	0.548
Chronic kidney disease, n (%)	86 (48.3)	9 (29.0)	<b>0.047</b>
Previous Stroke, n (%)	15 (8.4)	4 (12.5)	0.453
Previous open-heart surgery, n (%)	26 (14.5)	2 (6.3)	0.204
Previous infectious endocarditis, n (%)	4 (2.3)	0 (0)	0.399
Logistic EuroSCORE, % (SD)	18.0 ± 12.0	14.2 ± 13.3	0.119
Left ventricular ejection fraction ± SD, %	57.8 ± 11.0	58.5 ± 12.4	0.749
Mean transaortic gradient, mean ± SD, mmHg	48.1 ± 16.1	49.3 ± 15.8	0.696
<b>Periprocedural characteristics</b>			
Implantation site			
Catheterization laboratory, n (%)	76 (42.5)	6 (18.8)	<b>0.030</b>
Operating hybrid room, n (%)	13 (7.3)	2 (6.3)	
Hybrid room	90 (50.3)	24 (75.0)	
Approach, n (%)			
Transfemoral	166 (92.7)	25 (78.1)	<b>0.009</b>
Prosthesis type			
Balloon-expandable, n (%)	88 (49.2)	21 (65.6)	0.086
Antibiotic prophylaxis			
B-Lactam alone, n (%)	149 (93.7)	28 (93.3)	0.082
Vancomycine alone or in combination, n (%)	8 (5.0)	0 (0)	
Other	2 (1.3)	2 (6.7)	
<b>In-hospital Outcomes (TAVR)</b>			
Acute renal failure, n (%)	23 (13.1)	4 (12.9)	0.980
Stroke, n (%)	7 (4.0)	2 (6.5)	0.533
Major vascular complication, n (%)	15 (8.5)	3 (9.7)	0.833
Major bleeding, n (%)	21 (11.9)	1 (3.2)	0.147
Sepsis, n (%)	18 (11.3)	4 (13.8)	0.694
New pacemaker implantation, n (%)	30 (16.8)	11 (34.4)	<b>0.020</b>

Residual aortic regurgitation >2 at discharge, n (%)	23 (13.2)	6 (1949)	0.366
Mean residual transaortic gradient, mean ± SD, mm Hg	11.3 ± 7.3	12.5 ± 4.3	0.417
Length of hospital stay, median [IQR], days	8 [6.0-16.0]	10 [5.0-13.0]	0.706
Time from TAVR, median [IQR], days	150.0 [35.0-424.0]	245.5 [87.5-432.5]	0.196
<b>Initial symptoms</b>			
Fever, n (%)	135 (76.7)	24 (75.0)	0.834
New-onset heart failure, n (%)	80 (45.5)	16 (50.0)	0.635
Neurological, n (%)	37 (21.1)	2 (6.3)	<b>0.048</b>
Systemic embolism, n (%)	23 (13.1)	5 (15.6)	0.706
Skin lesions	6 (3.4)	1 (3.1)	0.930
Health care-associated infection, n (%)	76 (42.5)	15 (46.9)	0.642
<b>Echocardiographic findings, No./total (%)</b>			
Perivalvular extension	27 (15.1)	8 (25.0)	0.165
Valves involved			
TAVR prosthesis alone, n (%)	73 (40.8)	14 (43.8)	
Mitral (native or prosthetic valve), n (%)	34 (19.0)	3 (9.4)	<b>0.011</b>
Multiple localization, n (%)	65 (36.3)	9 (28.1)	
Right sided endocarditis alone, n (%)	7 (3.9)	6 (18.8)	
Vegetation size [IQR], mm	10.0 [6.0-15.0]	11.0 [7-24]	0.355
<b>Causative microorganisms, No./total (%)</b>			
<i>Staphylococcus aureus</i> , n (%)	46 (27.7)	9 (28.1)	0.962
<i>Methicillin-resistant</i>	11/46 (23.9)	0/9 (0)	
Coagulase-negative Staphylococci, n (%)	22 (13.3)	10 (31.3)	<b>0.011</b>
<i>Methicillin-resistant</i>	8/22 (36.4)	1/10 (10.0)	
Enterococci, n (%)	46 (27.1)	6 (18.8)	0.292
Streptococci			
<i>S. Viridans</i> , n (%)	21 (12.7)	0 (0)	<b>0.033</b>
<i>S. gallopticus</i> ( <i>S. bovis</i> ), n (%)	5 (3.0)	2 (6.3)	0.364
Others, n (%)	6 (3.6)	0 (0)	0.275
Culture negative, n (%)	14 (8.4)	5 (15.6)	0.206
<b>Complications during IE hospitalization</b>			
<b>No./total (%)</b>			
Heart failure, n (%)	74/171 (43.3)	18/32 (56.3)	0.176
Acute renal failure, n (%)	59/158 (37.3)	13/31 (41.9)	0.630
Septic shock, n (%)	56/170 (32.9)	6 (18.8)	0.110
Stroke, n (%)	16/171 (9.4)	4/32 (12.5)	0.584
Systemic embolization, n (%)	16/170 (9.4)	6/32 (18.8)	0.120

Persistent bacteremia, n (%)	43/147 (29.3)	15/28 (57.1)	<b>0.004</b>
<b>Management and Outcomes, n (%)</b>			
In-hospital mortality, n (%)	63/176 (35.8)	10 (31.3)	0.620
Follow-up, median [IQR], months	5.0 [0.8-23.1]	5.5 [1.9-24.0]	0.241
30-day mortality rate, [95% CI], %	28.0 [22.0-35.2]	12.5 [5.9-48.8]	0.065
1-year mortality rate, [95% CI], %	53.1 [45.8-60.8]	44.4 [28.4-64.2)	0.246
2-year mortality rate, [95% CI], %	63.2 [55.6-70.8]	53.3 [35.9-72.9]	0.203

\*by log-rank

**Supplemental Table S2 – Univariate and multivariate analysis of IE hospitalization events associated with mortality in men**

	Univariate Analysis	Unadjusted	Multivariate Analysis	Adjusted
	Hazard Ratio (95% CI)	p-value	Hazard Ratio (95% CI)	p-value
<b>Complications during IE hospitalization</b>				
Heart failure	2.88 [2.09-3.97]	<0.001	1.51 [1.01-2.26]	0.046
Acute renal failure	3.74 [2.66-5.26]	<0.001	2.47 [1.66-3.67]	<0.001
Septic shock	5.09 [3.69-7.02]	<0.001	2.24 [1.51-3.32]	<0.001
Stroke	1.68 [1.07-2.64]	0.034		
Systemic embolization	1.20 [0.73-1.97]	0.469		
Persistent bacteraemia	3.96 [2.80-5.59]	<0.001	2.33 [1.59-3.41]	<0.001
<b>Management</b>				
Surgery	1.10 [0.75-1.58]	0.657		0.266

## **Supplemental Appendix S1. ACKNOWLEDGEMENT**

***We would like to acknowledge the Infectious Endocarditis after TAVR International Registry***

***Investigators for they substantial contribution to data collection and research:***

ABDEL-WAHAB Mohamed, MD, Heart Center, Leipzig University, Leipzig, Germany

ABIZAID Alexandre, MD, InCor, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil

ACTIS DATO Guglielmo Mario, MD, Ospedali Mauriziano, Torino, Italy

ALFONSO Fernando, MD, Hospital Universitario de La Princesa, Madrid, Spain

ALKHODAIR Abdullah, MD, St Paul's Hospital, Vancouver, Canada

ALPERI Alberto, MD, Hospital Universitario Central de Asturias, Oviedo, Spain

AMAT-SANTOS Ignacio, MD, PhD, CIBERCV, Hospital Clinico Universitario de Valladolid, Valladolid, Spain

ANDREA Julio, MD, Clínica Sao Vicente, Rio de Janeiro, Brazil

AUFFRET Vincent, MD, Univ Rennes, CHU Rennes, Inserm, LTSI - UMR1099, F 35000 Rennes, France

BARBANTI Marco, MD, A.O.U. Policlinico Vittorio Emanuele, University of Catania, Catania, Italy

BARTORELLI Antonio L., MD, Centro Cardiologico Monzino, IRCCS and Department of Biomedical and Clinical Sciences “Luigi Sacco”, University of Milan, Milan, Italy

BOUKHRIS Marouane, MD, Centre Hospitalier de l'Université de Montreal, Montreal, Canada

CAMPELO-PARADA Francisco, MD, Hôpital Rangueil, Toulouse, France

CASTILLO Juan Carlos, MD, Hospital Universitario Reina Sofia, Cordoba, Spain

CHAKRAVARTY, Tarun MD, Cedars-Sinai Heart Institute, Los Angeles, USA

CHAMANDI Chekrallah, MD, Hôpital Européen Georges-Pompidou, Paris, France

CHEEMA Asim N., MD, St Michaels Hospital, Toronto, Canada

COLAFRANCESCHI Alexandre Siciliano, MD, Hospital Pró-cardíaco, Rio de Janeiro, Brazil

CORREIA DE LIMA Valter, MD, Hospital São Francisco-Santa Casa de Porto Alegre, Porto Alegre, Brazil

CRUSIUS Lisa, MD, Heart Center, Leipzig University, Leipzig

DEL VAL David, MD, Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada

DURAND Eric, MD, Normandie Univ, UNIROUEN, U1096, CHU Rouen, Department of Cardiology, F-76000 Rouen, France

ELTCHANINOFF Helene, MD, Normandie Univ, UNIROUEN, U1096, CHU Rouen, Department of Cardiology, F-76000 Rouen, France

ESTEVES Vinicius, MD, Hospital Sao Luiz, Sao Paulo, Brazil;

FERREIRA Maria-Cristina, MD, Hospital Naval Marcilio Dias, Rio de Janeiro, Brazil

FIORINA Claudia, MD, ASST-Spedali Civili di Brescia, Brescia, Italy

GERVAIS, Philippe MD, Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada

GIANNINI Francesco, MD, Ospedale San Raffaele, Milan, Italy

GODINHO Roger R., MD, Hospital Samaritano Paulista, Sao Paulo, Brazil

GUTIÉRREZ-IBANES Enrique, MD, Instituto de Investigación Universitaria Gregorio Marañon, Hospital Gregorio Marañon, Madrid, Spain

HERNANDEZ-ANTOLIN Rosana, MD, Hospital Universitario Ramón y Cajal, Madrid

HERRMANN Howard C, MD, Hospital of the University of Pennsylvania, Philadelphia, USA

HIMBERT Dominique, MD, Bichat Hôpital, Paris, France

HOLZHEY David MD, Heart Center, Leipzig University, Leipzig

HUCZEK Zenon, MD, PhD Department of Cardiology, Medical University of Warsaw, Poland

HUSSER Oliver, MD, Deutsches Herzzentrum München, Munich, Germany;

IHLEMANN Nikolaj, MD, Rigshospitalet, Copenhagen, Denmark

KAPADIA Samir, MD, Cleveland Clinic, Cleveland, USA

KAPPERT Utz, MD, Herzzentrum Dresden, Technische Universität Dresden

KIM Won-Keun, MD, Kerckhoff Heart and Thorax Centre, Bad Nauheim, Germany

KINI Annapoorna S, MD, Mount Sinai Hospital, New York, NY, USA

KODALI Susheel, MD, Columbia University Medical Center, New York, USA;

LANDT Martin, MD, Heart Center, Segeberger Kliniken, Bad Segeberg, Germany

LATIB Azeem, MD, Ospedale San Raffaele, Milan, Italy

LE BRETON Hervé, MD, Univ Rennes, CHU Rennes, Inserm, LTSI - UMR1099, F 35000  
Rennes, France

LERAKIS, Stamatios MD, Emory University School of Medicine, Atlanta, USA

LINKE Axel, MD, Heart Center, Leipzig University, Leipzig

LISKO John, MD, Emory University School of Medicine, Atlanta, USA

LIVI Ugolino, MD, University Hospital of Udine, Udine, Italy

MAES Frédéric, MD, Cliniques Universitaires Saint-Luc, Brussels, Belgium

MAKKAR Raj, MD, Cedars-Sinai Heart Institute, Los Angeles

MANGIONE Jose Armando, MD, Hospital Beneficencia Portuguesa, Sao Paulo, Brazil

MANGNER Norman, MD, Heart Center, Leipzig University, Leipzig, Germany

MARINO Marcos Antonio, MD, Hospital Madre Teresa, Belo Horizonte, Brazil

MASSON Jean-Bernard, MD, Centre Hospitalier de l'Université de Montreal, Montreal,  
Canada

MICELI Antonio, MD, Istituto Clinico Sant'Ambrogio, Milan, Italy

MUNOZ-GARCIA Erika, MD, Hospital Universitario Virgen de la Victoria, Malaga, Spain

NOMBELA-FRANCO Luis, MD, Cardiovascular Institute, Hospital Clínico San Carlos, IdISSC, Madrid, Spain

OLIVARES Paolo, MD, Centro Cardiologico Monzino, IRCCS and Department of Biomedical and Clinical Sciences “Luigi Sacco”, University of Milan, Milan, Italy

PANAGIDES Vassili, MD, Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada

PASCUAL Isaac, MD, Hospital Universitario Central de Asturias, Oviedo, Spain;;

PELLEGRINI, Costanza MD, Deutsches Herzzentrum München, Munich, Germany

REGUEIRO Ander, MD, Hospital Clinic, Barcelona, Spain

RIBEIRO Henrique B., MD, InCor, Heart Institute, University of São Paulo Medical School, Sao Paulo, Brazil

RODÉS-CABAU Josep, MD, Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada

ROMAGUERA Rafael, MD, Hospital de Bellvitge, L'Hospitalet de Llobregat, Spain

ROSATO Francesco, MD, Azienda Ospedaliera S. Cocco e Carle, Cuneo, Italy

SALIDO Luisa, MD, Hospital Universitario Ramón y Cajal, Madrid, Spain

SANDOLI DE BRITO Fabio Jr, MD, InCor, Heart Institute, University of São Paulo Medical School, Sao Paulo, Brazil

SCISLO Piotr, MD, PhD, Department of Cardiology, Medical University of Warsaw, Poland

SERRA Vicenç, MD, Hospital Vall d'Hebron, Barcelona, Spain

SERVOZ Clement, MD, Hôpital Rangueil, Toulouse, France

SIDDIQUI Saif, MD, Clinique Pasteur, Toulouse, France

SINNING Jan Malte, MD, Heart Center Bonn, Bonn, Germany

SØNDERGAARD Lars, MD, Righospitalet, Copenhagen, Denmark

SPONGA Sandro, MD, University Hospital of Udine, Udine, Italy

STORTECKY Stefan, MD, Department of Cardiology, Inselspital, Bern University Hospital,  
University of Bern, Bern, Switzerland (on behalf of Swiss TAVI)

TCHETCHE Didier, MD, Clinique Pasteur, Toulouse, France

TESTA Luca, MD, IRCCS Pol. San Donato, Milan, Italy

URENA Marina, MD, Bichat Hôpital, Paris, France

VILALTA Victoria, MD, Hospital Germans Trias i Pujol, Badalona, Spain

WEBB John G, MD, St Paul's Hospital, Vancouver, Canada

WIJEYSUNDERA Harindra C, MD, Sunnybrook Health Science Center, Toronto, Canada

***Dr Rodés-Cabau*** holds the Research Chair "Fondation Famille Jacques Larivière" for the Development of Structural Heart Disease Interventions.

***Dr Panagides*** has received a research grant from the "*Mediterranean Academic Research and Studies in Cardiology*" association (MARS Cardio).